Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Total Current Liabilities
All obligations due within one year.
Forte Biosciences, Inc.NASDAQ: FBRX
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities rises 161.8% from a year ago
Total current liabilities stood at $23.65M at the end of Q1 FY2026, up 161.8% from a year earlier and up 14.0% from the prior quarter. Over 3 fiscal years it compounded at +86.9% a year.
Context
- Total current liabilities amounted to 35.2% of total assets at the end of Q1 FY2026, up 16.1 pp from a year earlier.
- Total current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps rising in the next quarterly balance sheet after a +161.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 20.75M USD
- Year-over-year change
- +128.5%
- 4-year CAGR
- +85.4%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.75M | +128.5% |
| FY2024 | 2024-12-31 | 9.08M | +147.7% |
| FY2023 | 2023-12-31 | 3.67M | +15.3% |
| FY2022 | 2022-12-31 | 3.18M | +80.8% |
| FY2021 | 2021-12-31 | 1.76M | — |
Total Current Liabilities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +161.8% is the highest of 10, against a peer median of -2.9%.
- Total current liabilities amounts to 35.2% of total assets for FBRX, versus a peer median of 12.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $40.97M USD | -62.7% | -9.5% | 17.1% | |
| Mar 2026 | $30.69M USD | +9.0% | -31.9% | 10.8% | |
| Mar 2026 | $23.65M USD | +161.8% | +86.9% | 35.2% | |
| Mar 2026 | $18.21M USD | -2.9% | +0.3% | 4.9% | |
| Mar 2026 | $18.14M USD | +56.1% | +17.9% | 12.6% | |
| Mar 2026 | $14.46M USD | +8.8% | +28.1% | 29.4% | |
| Mar 2026 | $8.96M USD | -56.1% | -12.4% | 5.7% | |
| Mar 2026 | CHF 8.77M CHF | -2.1% | -13.9% | 10.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $7.23M USD | -36.7% | +5.7% | 31.9% |
ACTUActuate Therapeutics Inc | Mar 2026 | $4.72M USD | -48.4% | +9.5% | 53.0% |
| Peer median (excluding FBRX) | — | -2.9% | +0.3% | 12.6% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.